LFG
BCAX

Larson Financial Group’s Bicara Therapeutics BCAX Stock Holding History

Larson Financial Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
3,505
+10
+0.3% +$223 ﹤0.01% 1161
2026
Q1 		$69.5K Sell
3,495
-64
-2% -$1.1K ﹤0.01% 1170
2025
Q4 		$59.9K Sell
3,559
-390
-10% -$6.66K ﹤0.01% 1150
2025
Q3 		$62.4K Buy
3,949
+3,595
+1,016% +$40.2K ﹤0.01% 1073
2025
Q2 		$3.29K Sell
354
-716
-67% -$8.53K ﹤0.01% 2245
2025
Q1 		$13.9K Buy
+1,070
New +$14.2K ﹤0.01% 1504

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's BCAX Position: Q2 2026 in Review

Larson Financial Group increased its Bicara Therapeutics (BCAX) stake by 0.29% in Q2 2026, buying an estimated $223 and bringing the position to 3,505 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Larson Financial Group first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Larson Financial Group held 3,505 shares of Bicara Therapeutics worth $104K as of Q2 2026.
  • Larson Financial Group bought 10 Bicara Therapeutics shares in Q2 2026, an estimated $223.
  • Bicara Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1161 holding.
  • Larson Financial Group first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.